Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 46

1.

A Rare Case of Localized Argyria on the Face.

Isak V, Beerli T, Cozzio A, Flatz L.

Case Rep Dermatol. 2019 Feb 13;11(1):23-27. doi: 10.1159/000494610. eCollection 2019 Jan-Apr.

2.

Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.

Berner F, Bomze D, Diem S, Ali OH, Fässler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, Cruz CG, van de Veen W, Akdis M, Nikolaev S, Läubli H, Zippelius A, Hartmann F, Cheng HW, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy AN, Jochum W, Speiser DE, Flatz L.

JAMA Oncol. 2019 Apr 25. doi: 10.1001/jamaoncol.2019.0402. [Epub ahead of print]

3.

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.

Fässler M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Del Carmen Gil Cruz C, Pérez Shibayama CI, Krolik M, Siano M, Joerger M, Recher M, Risch L, Güsewell S, Risch M, Speiser DE, Ludewig B, Levesque MP, Dummer R, Flatz L.

J Immunother Cancer. 2019 Feb 20;7(1):50. doi: 10.1186/s40425-019-0523-2.

4.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.

Diem S, Fässler M, Bomze D, Ali OH, Berner F, Niederer R, Hillmann D, Mangana J, Levesque MP, Dummer R, Risch L, Recher M, Risch M, Flatz L.

J Immunother. 2019 Apr;42(3):89-93. doi: 10.1097/CJI.0000000000000255.

PMID:
30768543
5.

A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H.

Clin Cancer Res. 2019 May 15;25(10):3026-3034. doi: 10.1158/1078-0432.CCR-18-3041. Epub 2019 Feb 14.

PMID:
30765392
6.

Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation.

Hartwig T, Zwicky P, Schreiner B, Yawalkar N, Cheng P, Navarini A, Dummer R, Flatz L, Conrad C, Schlapbach C, Becher B.

Cell Rep. 2018 Dec 26;25(13):3564-3572.e4. doi: 10.1016/j.celrep.2018.12.012.

7.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L.

Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009. Epub 2018 Dec 7.

8.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.

Diem S, Fässler M, Ali OH, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L.

Cancer Manag Res. 2018 Nov 8;10:5537-5544. doi: 10.2147/CMAR.S179767. eCollection 2018.

9.

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).

Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M.

Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832. doi: 10.1007/s00262-018-2239-4. Epub 2018 Aug 31.

PMID:
30171269
10.

Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.

Fischer S, Ali OH, Jochum W, Kluckert T, Flatz L, Siano M.

Oncol Res Treat. 2018;41(6):391-394. doi: 10.1159/000487084. Epub 2018 May 3.

PMID:
29734143
11.

Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.

Diem S, Hasan Ali O, Ackermann CJ, Bomze D, Koelzer VH, Jochum W, Speiser DE, Mertz KD, Flatz L.

Cancer Immunol Immunother. 2018 Jan;67(1):39-45. doi: 10.1007/s00262-017-2061-4. Epub 2017 Sep 11.

PMID:
28894934
12.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.

Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.

PMID:
28838390
13.

Interferon-γ-Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever.

Remy MM, Sahin M, Flatz L, Regen T, Xu L, Kreutzfeldt M, Fallet B, Doras C, Rieger T, Bestmann L, Hanisch UK, Kaufmann BA, Merkler D, Pinschewer DD.

Cell Host Microbe. 2017 Sep 13;22(3):354-365.e5. doi: 10.1016/j.chom.2017.07.008. Epub 2017 Aug 17.

14.

Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression.

Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS.

Nat Commun. 2017 Mar 1;8:14447. doi: 10.1038/ncomms14447.

15.

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L.

Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016.

16.

GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman AJ, Mueller J, Flatz L.

JAAD Case Rep. 2016 Oct 13;2(5):415-417. eCollection 2016 Sep. No abstract available.

17.

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L.

J Immunother. 2016 Nov/Dec;39(9):379-382.

18.

Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.

Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M.

BMC Cancer. 2016 Aug 19;16:656. doi: 10.1186/s12885-016-2718-y.

19.

Generation of Lymphocytic Choriomeningitis Virus Based Vaccine Vectors.

Ring S, Flatz L.

Methods Mol Biol. 2016;1404:351-64. doi: 10.1007/978-1-4939-3389-1_24.

PMID:
27076310
20.

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.

Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. doi: 10.1073/pnas.1512832112. Epub 2015 Nov 25.

Supplemental Content

Loading ...
Support Center